JP7868066B2 - 線維症を処置する方法 - Google Patents
線維症を処置する方法Info
- Publication number
- JP7868066B2 JP7868066B2 JP2023547328A JP2023547328A JP7868066B2 JP 7868066 B2 JP7868066 B2 JP 7868066B2 JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 7868066 B2 JP7868066 B2 JP 7868066B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- dose
- fibrosis
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026084780A JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091128P | 2020-10-13 | 2020-10-13 | |
| US63/091,128 | 2020-10-13 | ||
| PCT/US2021/054713 WO2022081661A1 (en) | 2020-10-13 | 2021-10-13 | Methods of treating fibrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026084780A Division JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546536A JP2023546536A (ja) | 2023-11-02 |
| JP2023546536A5 JP2023546536A5 (cg-RX-API-DMAC7.html) | 2024-11-14 |
| JP7868066B2 true JP7868066B2 (ja) | 2026-06-01 |
Family
ID=81209448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547328A Active JP7868066B2 (ja) | 2020-10-13 | 2021-10-13 | 線維症を処置する方法 |
| JP2026084780A Pending JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026084780A Pending JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11628167B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4229828A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7868066B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230107568A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116349204A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021360767A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198661A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022081661A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605377B2 (en) | 2020-10-13 | 2026-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| JP7868066B2 (ja) | 2020-10-13 | 2026-06-01 | エンデバー バイオメディシンズ, インコーポレイテッド | 線維症を処置する方法 |
| CN120916760A (zh) * | 2023-02-28 | 2025-11-07 | 奋进生物医药公司 | 治疗纤维化的方法 |
| US12447148B2 (en) | 2024-03-05 | 2025-10-21 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530705A (ja) | 2009-06-19 | 2012-12-06 | イーライ リリー アンド カンパニー | 二置換フタラジンヘッジホッグ経路アンタゴニスト |
| US20200000784A1 (en) | 2018-06-29 | 2020-01-02 | The Trustees Of Indiana University | Materials and methods for treating valvular heart diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (cg-RX-API-DMAC7.html) | 1977-06-03 | 1981-03-07 | Pfizer | |
| AU717744B2 (en) | 1996-01-15 | 2000-03-30 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
| JP5067986B2 (ja) | 1998-04-09 | 2012-11-07 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
| GB0013674D0 (en) | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| AU2003231032B2 (en) | 2002-04-22 | 2008-07-10 | Johns Hopkins University School Of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| EP1745039A4 (en) | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES |
| WO2006028958A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| US8536168B2 (en) | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
| US8153633B2 (en) | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| AU2008300019A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| CN102066353B (zh) | 2008-04-29 | 2013-12-11 | 伊莱利利公司 | 二取代的酞嗪Hedgehog通路拮抗剂 |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| CA2732101C (en) | 2008-08-04 | 2013-09-17 | Amgen Inc. | Aurora kinase modulators and methods of use |
| ES2418479T3 (es) | 2008-11-03 | 2013-08-14 | Eli Lilly And Company | Antagonistas de la ruta erizo de ftalazinas disustituidas |
| MX2011005177A (es) | 2008-11-17 | 2011-05-30 | Lilly Co Eli | Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas. |
| JP5518088B2 (ja) | 2008-11-17 | 2014-06-11 | イーライ リリー アンド カンパニー | 四置換ピリダジンヘッジホッグ経路アンタゴニスト |
| WO2011088404A1 (en) | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| US9970935B2 (en) * | 2014-02-06 | 2018-05-15 | The Brigham And Women's Hospital, Inc. | Uses of GLI1 in detecting tissue fibrosis |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| EP3383912A4 (en) | 2015-11-30 | 2019-11-06 | Ignyta, Inc. | TOPICAL FORMULATIONS |
| US20190255042A1 (en) * | 2016-11-04 | 2019-08-22 | Impact Therapeutics, Inc | Application of hedgehog pathway inhibitor in treating fibrosis diseases |
| CN112449602A (zh) * | 2018-07-19 | 2021-03-05 | 瓦里安医疗系统公司 | 超高剂量率辐射和治疗剂的使用方法 |
| JP7868066B2 (ja) | 2020-10-13 | 2026-06-01 | エンデバー バイオメディシンズ, インコーポレイテッド | 線維症を処置する方法 |
| US12605377B2 (en) | 2020-10-13 | 2026-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| CN120916760A (zh) | 2023-02-28 | 2025-11-07 | 奋进生物医药公司 | 治疗纤维化的方法 |
-
2021
- 2021-10-13 JP JP2023547328A patent/JP7868066B2/ja active Active
- 2021-10-13 CN CN202180069900.XA patent/CN116349204A/zh active Pending
- 2021-10-13 KR KR1020237015750A patent/KR20230107568A/ko active Pending
- 2021-10-13 WO PCT/US2021/054713 patent/WO2022081661A1/en not_active Ceased
- 2021-10-13 AU AU2021360767A patent/AU2021360767A1/en active Pending
- 2021-10-13 EP EP21880965.5A patent/EP4229828A4/en active Pending
- 2021-10-13 CA CA3198661A patent/CA3198661A1/en active Pending
-
2022
- 2022-05-03 US US17/735,798 patent/US11628167B2/en active Active
-
2023
- 2023-02-28 US US18/115,593 patent/US12295954B2/en active Active
-
2024
- 2024-06-26 US US18/755,445 patent/US12213974B2/en active Active
-
2025
- 2025-04-11 US US19/177,041 patent/US20250235452A1/en active Pending
-
2026
- 2026-05-20 JP JP2026084780A patent/JP2026124900A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530705A (ja) | 2009-06-19 | 2012-12-06 | イーライ リリー アンド カンパニー | 二置換フタラジンヘッジホッグ経路アンタゴニスト |
| US20200000784A1 (en) | 2018-06-29 | 2020-01-02 | The Trustees Of Indiana University | Materials and methods for treating valvular heart diseases |
Non-Patent Citations (2)
| Title |
|---|
| Horn, A. et al.,Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis,Annals of the Rheumatic Diseases,2012年,Vol.71, No.5,p.785-789,doi:10.1136/annrheumdis-2011-200883 |
| Ueno, H. et al.,A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors,Investigational New Drugs,2018年,Vol.36, No.4,p.647-656,doi:10.1007/s10637-017-0544-y |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220265650A1 (en) | 2022-08-25 |
| US11628167B2 (en) | 2023-04-18 |
| US20240342170A1 (en) | 2024-10-17 |
| WO2022081661A1 (en) | 2022-04-21 |
| US12295954B2 (en) | 2025-05-13 |
| AU2021360767A1 (en) | 2023-04-27 |
| US12213974B2 (en) | 2025-02-04 |
| JP2023546536A (ja) | 2023-11-02 |
| US20250235452A1 (en) | 2025-07-24 |
| EP4229828A1 (en) | 2023-08-23 |
| JP2026124900A (ja) | 2026-07-31 |
| EP4229828A4 (en) | 2024-08-28 |
| CA3198661A1 (en) | 2022-04-21 |
| CN116349204A (zh) | 2023-06-27 |
| KR20230107568A (ko) | 2023-07-17 |
| US20230201195A1 (en) | 2023-06-29 |
| AU2021360767A9 (en) | 2024-02-08 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241011 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251028 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260422 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260430 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260520 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7868066 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |